

Resource Summary Report

Generated by SPARC SAWG on Aug 16, 2026

Brilliant Violet 421(TM) anti-human CD19

RRID:AB_10897802

Type: Antibody

Proper Citation

BioLegend Cat# 302233, RRID:AB_10897802

Antibody Information

URL: http://antibodyregistry.org/AB_10897802

Proper Citation: BioLegend Cat# 302233, RRID:AB_10897802

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, ICC, IHC-F

Antibody Name: Brilliant Violet 421(TM) anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_10897802

Vendor: BioLegend

Catalog Number: 302233

Alternative Catalog Numbers: 302234

Record Creation Time: 20250820T025537+0000

Record Last Update: 20250820T145303+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD19.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Pulliam T, et al. (2024) Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma. Cell reports. Medicine, 5(2), 101412.

Cheung A, et al. (2024) Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(15), 3298.

Irrgang P, et al. (2023) Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Science immunology, 8(79), eade2798.

Fabra-García A, et al. (2023) Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes. Immunity, 56(2), 406.

Chauvin C, et al. (2023) Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. iScience, 26(3), 106124.

Stražar M, et al. (2023) HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery. Immunity, 56(7), 1681.

García-Vega M, et al. (2023) 19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern. iScience, 26(4), 106562.

de Silva TI, et al. (2021) The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. iScience, 24(11), 103353.

Cizmeci D, et al. (2021) Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. eLife, 10.

Schoofs T, et al. (2019) Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity, 50(6), 1513.

Usmani SM, et al. (2019) HIV-1 Balances the Fitness Costs and Benefits of Disrupting the Host Cell Actin Cytoskeleton Early after Mucosal Transmission. Cell host & microbe, 25(1), 73.